2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
5
Neoplasms
4
Stomach Neoplasms
3
Malnutrition
3
Lung Neoplasms
3
Diarrhea
3
Uterine Cervical Neoplasms
2
Mucositis
2
Inflammation
2
Enteritis
2
Chalazion
2
Carcinoma, Hepatocellular
2
Thyroid Neoplasms
1
Squamous Intraepithelial Lesions
1
Smoldering Multiple Myeloma
1
Radiation Injuries
1
Psychological Well-Being
1
Psoriasis Vulgaris
1
Polycystic Ovary Syndrome
1
Periampullary Carcinoma Nos
1
Pelvic Neoplasms
1
Pelvic Inflammatory Disease
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasms, Second Primary
1
Muscle Invasive Bladder Cancer (MIBC)
1
Multiple Myeloma
1
Motor Activity
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Carboplatin
72
Docetaxel
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
42
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Probiotics
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled